File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Attainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kong

TitleAttainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kong
Authors
KeywordsCoronary heart disease
High-lipoprotein cholesterol
Hong Kong
Lipid-modifying therapy
Low-density lipoprotein
Risk factors
Statin
Triglyceride
Issue Date2012
PublisherSpringer Healthcare Communications Ltd. The Journal's web site is located at http://www.springerhealthcare.com/ait/index.htm
Citation
Advances in Therapy: the international journal of drug, device and diagnostic research, 2012, v. 29 n. 5, p. 427-441 How to Cite?
AbstractINTRODUCTION: Although low-density lipoprotein cholesterol (LDL-C) is the primary lipid target for coronary heart disease (CHD) risk reduction, high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) have also emerged as CHD risk factors. The objective of this study was to evaluate attainment of lipid goals and normal levels following lipid-modifying therapy (LMT) and its predictors in a representative sample of Chinese patients from Hong Kong. METHODS: Using longitudinal data collected from patient medical records, the study identified 706 patients who initiated LMT from January 2004 to December 2006 and had full lipid panels 12 months before and after therapy. LDL-C goals and normal levels of HDL-C and TG were defined according to the National Cholesterol Education Program Adult Treatment Panel 3 guidelines. Patients with previous CHD, diabetes, and 10-year CHD risk > 20% were classified as high risk. Multiple logistic regressions evaluated predictors of normal lipid-level attainment. RESULTS: Among 706 patients (mean age 64.6 years, 58.6% male), 71.7% had elevated LDL-C, 32.4% had low HDL-C, and 24.9% had elevated TG before LMT. Despite therapy (91.2% statins only), 22.7% had elevated LDL-C, 31.9% had low HDL-C, 12.3% had elevated TG, and 13.9% had multiple abnormal lipid levels. The strongest predictors of attaining >/= 2 normal lipid levels included male gender (odds ratio [OR]: 2.11 [1.12 to 4.01]), diabetes (OR: 0.43 [0.23 to 0.78]), obesity (OR: 0.91 [0.86 to 0.97]), and CHD risk > 20% (OR: 0.33 [0.15 to 0.71]). CONCLUSIONS: Current approaches to lipid management in Hong Kong, primarily using statins, considerably improve attainment of LDL-C goal. However, a large proportion of patients do not achieve normal HDL-C levels and control of multiple lipid parameters remains poor. Patients could benefit from a more comprehensive approach to lipid management that treats all three lipid risk factors, as suggested in clinical guidelines.
Persistent Identifierhttp://hdl.handle.net/10722/163513
ISSN
2015 Impact Factor: 2.503
2015 SCImago Journal Rankings: 0.790
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorAmbegaonkar, Ben_US
dc.contributor.authorChirovsky, Den_US
dc.contributor.authorTse, HFen_US
dc.contributor.authorLau, YKen_US
dc.contributor.authorTomlinson, Ben_US
dc.contributor.authorLi, SKen_US
dc.contributor.authorYue, CSen_US
dc.contributor.authorWong, THen_US
dc.contributor.authorChoi, MCen_US
dc.contributor.authorTunggal, Pen_US
dc.contributor.authorTan, KCBen_US
dc.contributor.authorSazonov, Ven_US
dc.date.accessioned2012-09-05T05:32:52Z-
dc.date.available2012-09-05T05:32:52Z-
dc.date.issued2012en_US
dc.identifier.citationAdvances in Therapy: the international journal of drug, device and diagnostic research, 2012, v. 29 n. 5, p. 427-441en_US
dc.identifier.issn0741-238Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/163513-
dc.description.abstractINTRODUCTION: Although low-density lipoprotein cholesterol (LDL-C) is the primary lipid target for coronary heart disease (CHD) risk reduction, high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) have also emerged as CHD risk factors. The objective of this study was to evaluate attainment of lipid goals and normal levels following lipid-modifying therapy (LMT) and its predictors in a representative sample of Chinese patients from Hong Kong. METHODS: Using longitudinal data collected from patient medical records, the study identified 706 patients who initiated LMT from January 2004 to December 2006 and had full lipid panels 12 months before and after therapy. LDL-C goals and normal levels of HDL-C and TG were defined according to the National Cholesterol Education Program Adult Treatment Panel 3 guidelines. Patients with previous CHD, diabetes, and 10-year CHD risk > 20% were classified as high risk. Multiple logistic regressions evaluated predictors of normal lipid-level attainment. RESULTS: Among 706 patients (mean age 64.6 years, 58.6% male), 71.7% had elevated LDL-C, 32.4% had low HDL-C, and 24.9% had elevated TG before LMT. Despite therapy (91.2% statins only), 22.7% had elevated LDL-C, 31.9% had low HDL-C, 12.3% had elevated TG, and 13.9% had multiple abnormal lipid levels. The strongest predictors of attaining >/= 2 normal lipid levels included male gender (odds ratio [OR]: 2.11 [1.12 to 4.01]), diabetes (OR: 0.43 [0.23 to 0.78]), obesity (OR: 0.91 [0.86 to 0.97]), and CHD risk > 20% (OR: 0.33 [0.15 to 0.71]). CONCLUSIONS: Current approaches to lipid management in Hong Kong, primarily using statins, considerably improve attainment of LDL-C goal. However, a large proportion of patients do not achieve normal HDL-C levels and control of multiple lipid parameters remains poor. Patients could benefit from a more comprehensive approach to lipid management that treats all three lipid risk factors, as suggested in clinical guidelines.en_US
dc.languageengen_US
dc.publisherSpringer Healthcare Communications Ltd. The Journal's web site is located at http://www.springerhealthcare.com/ait/index.htmen_US
dc.relation.ispartofAdvances in Therapy: the international journal of drug, device and diagnostic researchen_US
dc.rightsThe original publication is available at www.springerlink.com-
dc.subjectCoronary heart disease-
dc.subjectHigh-lipoprotein cholesterol-
dc.subjectHong Kong-
dc.subjectLipid-modifying therapy-
dc.subjectLow-density lipoprotein-
dc.subjectRisk factors-
dc.subjectStatin-
dc.subjectTriglyceride-
dc.subject.meshCoronary Disease - epidemiology - prevention and control-
dc.subject.meshHydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use-
dc.subject.meshHyperlipidemias - blood - drug therapy - epidemiology-
dc.subject.meshLipids - blood-
dc.titleAttainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kongen_US
dc.typeArticleen_US
dc.identifier.emailTse, HF: hftse@hku.hken_US
dc.identifier.emailTan, KCB: kcbtan@hku.hk-
dc.identifier.authorityTse, HF=rp00428en_US
dc.identifier.authorityTan, KCB=rp00402en_US
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s12325-012-0017-9en_US
dc.identifier.pmid22562782-
dc.identifier.scopuseid_2-s2.0-84863716578en_US
dc.identifier.hkuros203994-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84863716578&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume29en_US
dc.identifier.issue5en_US
dc.identifier.spage427en_US
dc.identifier.epage441en_US
dc.identifier.isiWOS:000305225900004-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridSazonov, V=25031764700en_US
dc.identifier.scopusauthoridTan, KCB=8082703100en_US
dc.identifier.scopusauthoridTunggal, P=54394619800en_US
dc.identifier.scopusauthoridChoi, MC=55206006000en_US
dc.identifier.scopusauthoridWong, TH=55207496100en_US
dc.identifier.scopusauthoridYue, CS=55206248500en_US
dc.identifier.scopusauthoridLi, SK=55207162900en_US
dc.identifier.scopusauthoridTomlinson, B=54911672100en_US
dc.identifier.scopusauthoridLau, YK=35765428400en_US
dc.identifier.scopusauthoridTse, HF=54886126900en_US
dc.identifier.scopusauthoridChirovsky, D=34968928900en_US
dc.identifier.scopusauthoridAmbegaonkar, B=16038757500en_US
dc.identifier.citeulike10666091-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats